/ CORRECTION - AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008

Market Wire, April, 2008

In the news release "AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008," issued earlier today by AtheroGenics, Inc. (NASDAQ: AGIX), we are advised by the company that the time of the webcast in paragraph one should read "11:10 a.m. EDT" rather than "11:20 a.m. EDT" as originally issued. Complete corrected text follows.

AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008

ATLANTA, GA -- April 30, 2008 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced its participation in the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Friday, May 2, 2008 at 11:10 a.m. EDT.

The conference will feature its "Unplugged" presentation format with Morgan Stanley analysts hosting company management in an informal and interactive discussion with the investment community.

A live webcast of the Company's presentation may be accessed from 'Investor Relations' on the Company's website at www.atherogenics.com . The replay of the webcast will also be available on the Company's website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com .

CONTACTS: AtheroGenics, Inc. Donna Glasky Corporate Communications 678-336-2517 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact